Bioxytran’s BXT-25 Drug Acts as a Universal Oxygen Carrier Like Hyperbaric Oxygenation for Stroke and Alzheimer’s Patients
BXT-25 is expected to oxygenate the brain and be monitored by Bioxytran’s FDA approved medical device to trace all oxygen molecules BOSTON, MASSACHUSETTS, July 8, 2024 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer’s disease, announced that Bioxtran’s Science Advisor Prof. Avraham Mayevsky’s book titled Hyperbaric Oxygenation Mitochondrial Activity and Brain Physiological Functions was published by a publishing house, Springer. It is available by eBook or Hardcover.
Read more